Scopolamine Causes Delirium-Like Brain Network Dysfunction and Reversible Cognitive Impairment Without Neuronal Loss.

Qing Wang,Xiang Zhang,Yu-Jie Guo,Ya-Yan Pang,Jun-Jie Li,Yan-Li Zhao,Jun-Fen Wei,Bai-Ting Zhu,Jing-Xiang Tang,Yang-Yang Jiang,Jie Meng,Ji-Rong Yue,Peng Lei
DOI: https://doi.org/10.24272/j.issn.2095-8137.2022.473
2023-01-01
Zoological Research
Abstract:Delirium is a severe acute neuropsychiatric syndrome that commonly occurs in the elderly and is considered an independent risk factor for later dementia. However, given its inherent complexity, few animal models of delirium have been established and the mechanism underlying the onset of delirium remains elusive. Here, we conducted a comparison of three mouse models of delirium induced by clinically relevant risk factors, including anesthesia with surgery (AS), systemic inflammation, and neurotransmission modulation. We found that both bacterial lipopolysaccharide (LPS) and cholinergic receptor antagonist scopolamine (Scop) induction reduced neuronal activities in the delirium-related brain network, with the latter presenting a similar pattern of reduction as found in delirium patients. Consistently, Scop injection resulted in reversible cognitive impairment with hyperactive behavior. No loss of cholinergic neurons was found with treatment, but hippocampal synaptic functions were affected. These findings provide further clues regarding the mechanism underlying delirium onset and demonstrate the successful application of the Scop injection model in mimicking delirium-like phenotypes in mice.
What problem does this paper attempt to address?